TFA
ACAD icon

Transamerica Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Transamerica Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
4,118
+574
+16% +$12.6K 0.01% 568
2026
Q1 		$78.9K Buy
3,544
+2,209
+165% +$52.8K 0.01% 580
2025
Q4 		$35.7K Buy
1,335
+1,005
+305% +$24K ﹤0.01% 600
2025
Q3 		$7.04K Buy
+330
New +$7.8K ﹤0.01% 801
2017
Q1 		– Sell
-36
Closed -$2K – 394
2016
Q4 		$2K Buy
+36
New +$952 ﹤0.01% 290

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Transamerica Financial Advisors's ACAD Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 16% in Q2 2026, buying an estimated $12.6K and bringing the position to 4,118 shares worth $104K. The position accounts for 0.01% of the portfolio, ranked #568.

Transamerica Financial Advisors first reported a position in ACAD in Q4 2016 and has held it in 5 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Transamerica Financial Advisors held 4,118 shares of Acadia Pharmaceuticals worth $104K as of Q2 2026.
  • Transamerica Financial Advisors bought 574 Acadia Pharmaceuticals shares in Q2 2026, an estimated $12.6K.
  • Acadia Pharmaceuticals made up 0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #568 holding.
  • Transamerica Financial Advisors first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.